LAVA Therapeutics NV
NASDAQ:LVTX

Watchlist Manager
LAVA Therapeutics NV Logo
LAVA Therapeutics NV
NASDAQ:LVTX
Watchlist
Price: 0.99 USD -9.17% Market Closed
Market Cap: 26m USD
Have any thoughts about
LAVA Therapeutics NV?
Write Note

LAVA Therapeutics NV
Pre-Tax Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

LAVA Therapeutics NV
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
LAVA Therapeutics NV
NASDAQ:LVTX
Pre-Tax Income
-$41.7m
CAGR 3-Years
-39%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Pharming Group NV
AEX:PHARM
Pre-Tax Income
-$17.2m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
2%
ProQR Therapeutics NV
NASDAQ:PRQR
Pre-Tax Income
-€24.1m
CAGR 3-Years
25%
CAGR 5-Years
14%
CAGR 10-Years
N/A
Uniqure NV
NASDAQ:QURE
Pre-Tax Income
-$234.9m
CAGR 3-Years
N/A
CAGR 5-Years
-18%
CAGR 10-Years
-18%
argenx SE
XBRU:ARGX
Pre-Tax Income
-$317.1m
CAGR 3-Years
15%
CAGR 5-Years
-26%
CAGR 10-Years
-53%
Merus NV
NASDAQ:MRUS
Pre-Tax Income
-$237.1m
CAGR 3-Years
-44%
CAGR 5-Years
-52%
CAGR 10-Years
N/A
No Stocks Found

LAVA Therapeutics NV
Glance View

Market Cap
26m USD
Industry
Biotechnology

LAVA Therapeutics NV operates as a biotechnology company, which develops immune oncology biopharmaceutical products. The company is headquartered in Utrecht, Utrecht and currently employs 55 full-time employees. The firm focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.

LVTX Intrinsic Value
2.18 USD
Undervaluation 55%
Intrinsic Value
Price

See Also

What is LAVA Therapeutics NV's Pre-Tax Income?
Pre-Tax Income
-41.7m USD

Based on the financial report for Dec 31, 2023, LAVA Therapeutics NV's Pre-Tax Income amounts to -41.7m USD.

What is LAVA Therapeutics NV's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 3Y
-39%

Over the last year, the Pre-Tax Income growth was -32%. The average annual Pre-Tax Income growth rates for LAVA Therapeutics NV have been -39% over the past three years .

Back to Top